Arkolith/Insider Trading/SPRO/Form 4

Keutzer Timothy

Chief Operating OfficerSpero Therapeutics, Inc. (SPRO) · full profile →Form 4 · filed Feb 5, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$101K
Net Open-Market Flow
-$101K
Transactions
5
4 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Feb 4, 2026Sell(S)3K$2.24$8K761K
Feb 3, 2026Sell(S)24K$2.14$52K765K
Feb 2, 2026Sell(S)19K$2.20$42K789K
Feb 2, 2026Grant(A)68K—$0808K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Feb 2, 2026Grant(A)137K—$0137K

Transaction Codes

S
Open-market sale
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001193125-26-038441) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML